Table 2. Fractions of tumor-reactive lymphocytes in large-scale expanded TIL from melanoma-invaded lymph nodes of 47 patients treated by TIL.

Patients	% IFN-γ-positive lymphocytesb		Relapse-free survivalc
	E1a	E2
M88*	ND	0.4	+
M110	0	0	−(7)
M113	10.3	0.8	−(6.5)
M117	ND	2.5	+
M125	0	2.4	−(3)
M131	0	0	−(5)
M132	0	0	−(2)
M134	0.7	0	+
M140	0	0	+
M153	0	0	−(3)
M154*	7.2	13.8	−(156)
M158	0	0	−(5)
M164	0	0	−(26)
M167	0.7	1.8	−(4)
M170*	1.2	ND	+
M171	0	0	−(3)
M177*	1.1	2.2	+
M182	0	0.7	+
M187	2.9	0.4	+
M193	3.5	4	−(4)
M196*	1	0	−(6)
M197*	2.9	0	+
M199	2.7	2.4	−(2)
M200	1	0.4	−(7)
M204	0	3.4	−(3)
M212	0.4	1	−(8)
M218*	9	11.3	+
M234*	4.9	2.3	−(26)
M241*	27.7	9.1	−(13)
M245*	19.7	11.3	−(8)
M252*	1.4	ND	−(2)
M254*	ND	2.2	+
M263*	2.56	1.49	−(14)
M275*	12.2	13	−(8.5)
M278*	21.5	11.6	+
M284*	2	4.7	+
M288*	0	1.5	+
M301*	13.2	14.7	−(6)
M305*	18.75	19.8	+
M314*	0.5	0.2	−(3.5)
M329*	3.4	4.2	−(27)
M379*	1.2	1.3	−(4)
M386*	1.1	0.9	+
M415*	5.8	2.2	+
M417*	0.56	0.89	+
M424*	ND	8	+
M428*	6.6	6.9	+

^*Melanoma patients bearing only one metastatic lymph node (early stage III patients).

^aE1 and E2 were TIL populations obtained and reinjected to the patient from respectively the first and the second ex-vivo expansions.

^bPercentages of IFN-γ secreting TIL were estimated by intracellular labeling. TIL were stimulated 6 h by autologous melanoma cells in presence of brefeldin A. Then, cells were fixed, permeabilized, stained for cytokine production and analyzed on a FACScalibur.

^cRelapse-free survival of patients (−): patients who relapsed,(months); (+): patients who did not relapse.